Celcuity to Participate in Cowen's 43rd Annual Health Care Conference

Rhea-AI Summary

MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity (NASDAQ:CELC), a biotechnology company focused on oncology therapies, will participate in Cowen's 43rd Annual Health Care Conference in Boston from March 6-8, 2023. CEO Brian Sullivan is scheduled to present on March 8 at 11:10 a.m. ET. The presentation will be available via live webcast at this link and can also be accessed through the company's Investors section. Celcuity's lead candidate, gedatolisib, is currently being evaluated in a Phase 3 trial for advanced breast cancer.

MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in Cowen's 43rd Annual Health Care Conference to be held in Boston on March 6-8, 2023.

Brian Sullivan, Chief Executive Officer and co-founder of Celcuity, is scheduled to present at 11:10 a.m. ET on Wednesday, March 8, 2023. A live webcast of the presentation will be available using this weblink: https://wsw.com/webcast/cowen132/celc/1975134. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. The company's CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Further information about Celcuity can be found at Celcuity.com. Follow us on LinkedIn and Twitter.

Contacts:

Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123

ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/741349/Celcuity-to-Participate-in-Cowens-43rd-Annual-Health-Care-Conference

FAQ

What conference will Celcuity participate in March 2023?

Celcuity will participate in Cowen's 43rd Annual Health Care Conference in Boston from March 6-8, 2023.

When is Celcuity's presentation at the Cowen Conference?

Celcuity's CEO Brian Sullivan will present on March 8, 2023, at 11:10 a.m. ET.

Where can I watch Celcuity's presentation live?

The live webcast of Celcuity's presentation can be accessed at this link or through the Investors section of their website.

What is gedatolisib and its significance for Celcuity?

Gedatolisib is Celcuity's lead therapeutic candidate, a pan-PI3K and mTOR inhibitor currently undergoing a Phase 3 trial for HR+/HER2- advanced breast cancer.

What trial is Celcuity conducting related to gedatolisib?

Celcuity is conducting the VIKTORIA-1 Phase 3 clinical trial, evaluating gedatolisib in combination with fulvestrant, with or without palbociclib.